Analysts Offer Predictions for JANX FY2025 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Janux Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.95) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $200.00 target price on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The business’s quarterly revenue was down 82.6% on a year-over-year basis.

A number of other equities analysts have also recently issued reports on JANX. HC Wainwright increased their target price on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. BTIG Research increased their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Stifel Nicolaus boosted their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. UBS Group assumed coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. Finally, Leerink Partners lifted their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Stock Up 0.5 %

Shares of JANX stock opened at $40.91 on Wednesday. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $71.71. The firm has a fifty day moving average of $52.59 and a 200-day moving average of $48.43. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -34.97 and a beta of 3.23.

Institutional Trading of Janux Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its holdings in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares in the last quarter. Plato Investment Management Ltd increased its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Avanza Fonder AB bought a new stake in Janux Therapeutics in the 4th quarter valued at about $139,000. Finally, AQR Capital Management LLC acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $215,000. 75.39% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the completion of the transaction, the chief executive officer now directly owns 257,054 shares in the company, valued at approximately $13,263,986.40. This represents a 8.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 108,334 shares of company stock valued at $6,070,020. 29.40% of the stock is currently owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.